# Clinical Trials Data EGFR - Document 96

# Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR

## Clinical Trial: https://clinicaltrials.gov/study/NCT01854034

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Histologically or cytologically confirmed stage IV or recurrent NSCLC\n\* Measurable disease by RECIST 1.0\n\* Must have received at least one prior line of therapy for advanced lung cancer (no maximum number)\n\* Life expectancy of at least 12 weeks\n\nExclusion Criteria:\n\n\* Pregnant or breastfeeding\n\* Radiation within 2 weeks\n\* Cytotoxic chemotherapy or monoclonal antibodies within 4 weeks\n\* EGFR tyrosine kinase inhibitor within 2 weeks\n\* Other small molecule inhibitor within 2 weeks\n\* Experimental treatment within 30 days\n\* Prior treatment with any HSP90 or HDAC inhibitor compound\n\* Known and untreated brain metastases\n\* History of allergic reactions attributed to compounds of similar chemical or biologic composition to AUY922\n\* Unresolved diarrhea greater than or equal to CTCAE version 4, grade 1\n\* Major surgery within 2 weeks of starting study drug or have not recovered from side effects of surgery\n\* Known disorders due to a deficiency in bilirubin glucuronidation\n\* Requiring use of therapeutic doses of warfarin (Coumadin)\n\* History of long QT syndrome\n\* History of clinically manifest ischemic heart disease, heart failure or left ventricular dysfunction\n\* Clinically significant ECG abnormalities\n\* Other clinically significant heart disease\n\* Currently receiving treatment with any medication which has a relative risk of prolonging the QTc interval or inducing Torsades de Pointes\n\* On a cardiac pacemaker\n\* Concurrent malignancies or invasive cancers diagnosed within 3 years except for adequately treated basal cell cancer of the skin or in situ cancer of the cervix\n\* Known to be HIV positive",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the eligibility criteria provided for this clinical trial, the presence of an EGFR gene mutation in a patient is not explicitly listed as either an inclusion or exclusion factor. However, there is an exclusion criterion regarding treatment with an "EGFR tyrosine kinase inhibitor within 2 weeks." This indicates that having received recent treatment with an EGFR tyrosine kinase inhibitor would make the patient ineligible, but the mutation itself is not a reason for exclusion.  
  
Therefore, a patient with an EGFR gene mutation could potentially be eligible for the trial as long as they have not received an EGFR tyrosine kinase inhibitor within the stipulated 2-week period before the start of the trial. Other criteria, such as having advanced NSCLC, meeting previous treatment requirements, and not meeting any of the other exclusion criteria, must also be fulfilled for eligibility.